Abstract Template

Title: Creating a vibrant and integrative ecosystem to accelerate translational oncology to make novel therapeutics and diagnostics widely accessible and affordable

Mandar V. Kulkarni

Elixsys Lifescience Inc., San Diego, USA

Keywords: Translational Oncology, Stakeholders, Collaboration, Leadership, Global research, Core facility

I. Abstract Body (up to 250 words)

Telecommunication has greatly improved global interactions. As we continue to connect individuals and organizations worldwide, the information overload has lead to significant dilution of several core messages required for effective collaboration. Therefore, our solutions focus on greatly improving the quality, effectiveness, efficiency, and outcome of the interaction among key collaborating stakeholders.

Elixsys has built a novel electronic platform, designed to bring together highly diverse stakeholders (i.e. research scientists, clinicians, biotechnologists, service providers, pharma, star-ups, and funding agencies (public and private) etc.) across the cancer care continuum. The cloud-based platform allows users to review expertise of others and initiate secure non-intrusive communication with a potential partner(s). Following a preliminary agreement to initiate a collaborative project, the users can form a closed subgroup for developing and managing the project through the "Group" management module within the platform's environment. The platform is specifically designed to integrate and streamline all the communication among the group members throughout the process of preliminary discussion, sourcing/raising funds, role assignment, and execution of the project without the need of handling multiple software programs.

The VCR Park is a physical infrastructure that brings together established world-class service providers (i.e. genomics, proteomics, bioinformatics, basic and advanced pathology, clinical trials, biobanking, animal experiments, training services) across the cancer care value chain on a single campus. The integrated services portfolio supports collaborative projects designed on the Elixsys platform and allows groups to conduct end-to-end R&D projects seamlessly. It also includes business development, regulatory, intellectual property, and commercialization services, which allows for efficient commercialization of products and services. Utilization of services and surrounding leased space is on an "as needed" basis instead of mandating the use of all services or minimum amount of space, thereby significantly reducing the cost of operations and development.

In addition, our extensive global network of organizations and individuals, operating in the cancer care domain, is presented as a resource for forging new partnerships. Together, this represents a global ecosystem established to address the ever-increasing burden of cancer and to translate oncology related innovations into world class products and services in a cost-effective manner.

II. Image:



III. Reference:

1 Horning SJ. A new cancer ecosystem. Science. 2017 Mar 17;355(6330):1103. doi: 10.1126/science.aan1295. PubMed PMID: 28302798.

2 Dangi-Garimella, Surabhi. “A Holistic Approach to Cancer Care: Focus on Collaboration.” AJMC, 19 Oct. 2016, www.ajmc.com/journals/evidence-based-oncology/2016/october-2016/A-Holistic-Approach-to-Cancer-Care-Focus-on-Collaboration. Accessed 5 Sept. 2017.

3 Institute of Medicine (US). Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington (DC): National Academies Press (US); 2010. Available from: https://www.ncbi.nlm.nih.gov/books/NBK210036/ doi: 10.17226/12930

4 Suzanne H. Reuben, Erin L. Milliken and Lisa J. Paradi, The Future Of Cancer Research: ACCELERATING SCIENTIFIC INNOVATION, President’s Cancer Panel Annual Report 2010-2011, Published by jointly by U.S. Department of health and human services, NIH and NCI.

IV. Biography:

Dr. Kulkarni completed his PhD in Molecular Oncology from Purdue University and Postdoctoral Studies from the Yale School of Medicine, New Haven, USA. He has been awarded the Young Investigator Award by the ACLPS and the FSG. He is the Chief Scientific Officer at Elixsys Lifescience, a premier translational oncology management consulting service organization. He has designed and managed over 150 genomics and bioinformatics projects and has extensive experience managing several stakeholders across the oncology product development value chain.

V. Presenting author details



Full Name: Mandar Kulkarni, PhD
Contact number: +91 8790006502
Twitter account: @mandri44
Linked In account: https://www.linkedin.com/in/mandar-kulkarni-ph-d-b161665/
Session name/ number:
Category: (Oral presentation)
Passport Number: US passport # 565761314